Skip to main content

Table 1 Summary of patients in whom follow-up management was evaluated (n = 193)

From: Survey of the initial management of celiac disease antibody tests by ordering physicians

 

Appropriate (n = 55)

Inappropriate (n = 46)

Technical (n = 19)

Nonresponders (n = 73)

Mean age at initial TTG (yrs)

9.9 +/− 5.2

9.1 +/− 4.8

9.9 +/−  5.0

9.2 +/−  5.25

Female, n (%)

27 (49.1)

23 (50.0)

13 (68.4)

49 (67.1)

EMA positive, n (%)

10 (16.7)

7 (15.2)

8 (42)

19 (26)

TTG, n (%)

  ≥ 10 x ULN

4 (7.3)

5 (10.9)

6 (31.6)

17 (23.3)

 3–10 x ULN

15 (27.3)

10 (21.7)

2 (10.5)

14 (19.2)

 1–3 x ULN

36 (65.4)

31 (67.4)

11 (57.9)

42 (57.5)

  1. EMA anti-endomysial antibody
  2. TTG tissue transglutaminase antibody
  3. ULN upper limit of normal
  4. The only statistical difference was between the appropriate & inappropriately managed patients with a TTG ≥ 10 x ULN (9/101) versus the nonresponders with a TTG ≥ 10 x ULN (17/73) (p < 0.05)